Printed From:

Structure Titration to Target Fasting Glucose

Titrate Lantus® long-acting insulin doses to help patients reach target fasting blood glucose levels.1 Two suggested titration options1-3,a


Adapted from Gerstein.4

FPG=fasting plasma glucose.

The dose of Lantus® should be adjusted according to blood glucose measurements to reach fasting plasma glucose (FPG) goal. The dosage of Lantus® should be individualized under the supervision of a treating healthcare professional in accordance with the needs of the patient.

  • Hypoglycemia may warrant a dose reduction
  • A reduction in the Lantus® dose may be required in patients with renal or hepatic impairment

aOther titration options are available. Lantus® should be used with oral antidiabetic drugs or rapid-acting insulin.


  1. Davies M, Storms F, Shutler S, et al. ATLantus Study Group. Diabetes Care. 2005;28(6):1282-1288.
  2. Yki-Järvinen H, Juurinen L, Alvarsson M, et al. Diabetes Care. 2007;30(6):1364-1369.
  3. Nathan DM, Buse JB, Davidson MB, et al. Diabetologia. 2009;52(1):17-30.
  4. Gerstein HC, Yale JF, Harris SB, Issa M, Stewart JA, Dempsey E. Diabet Med. 2006;23(7):736-742.

Proven HbA1c control

See how Lantus® provides effective, improved glycemic control in diabetes patients.

Lantus® Prescribing Information. February 2015.

Once-daily dosing

Lantus® is a once-daily, long-acting insulin.**

**Lantus® Prescribing Information. February 2015.

Demonstrated long-term CV safety

Lantus® is a basal insulin with demonstrated long-term CV safety data††

Including CV death, nonfatal MI, nonfatal stroke, revascularization, or hospitalization for heart failure. No difference was observed between Lantus® and standard of care in overall incidence of CV death, nonfatal MI, or nonfatal stroke. No difference was observed between treatment groups for death of any cause.